Feasibility and outcome of interval debulking surgery (IDS) after carboplatin-paclitaxel-bevacizumab (CPB): A subgroup analysis of the MITO-16A-MaNGO OV2A phase 4 trial
20% of patients underwent IDS in a large non-randomized trial, in Italy. 86.5% of the patients had residual disease ≤ 1 cm and 63.5% had no residual. 27 patients (38%) had the intervention complicated by, at least, one adverse event.